echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > JiMu Biotech announces the completion of over 100 million U.S. dollars in Series B financing

    JiMu Biotech announces the completion of over 100 million U.S. dollars in Series B financing

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 10th, Arctic Vision, an ophthalmic biotechnology company in the clinical development stage focusing on innovative therapies, announced today that it has completed a Series B financing of more than US$100 million.


    This round of financing was led by Zhengxingu Capital.


    JiMu’s current pipeline includes 3 phase 3 products introduced in the clinical phase, namely ARVN001 (Fengmai®) for the treatment of uveitis macular edema, ARVN002 for the treatment of progressive myopia in children, and ARVN003 for the treatment of presbyopia .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.